What Спазмомен Treats: Main Uses and Benefits

The primary role of this medication is to provide symptomatic relief by helping to ease the discomfort and pain associated with heightened physiological activity in the digestive system. It is commonly used in contexts where symptoms of increased muscular activity create noticeable physiological strain. The active ingredient in Спазмомен is generally used for managing conditions characterized by periods of heightened symptoms, such as Irritable Bowel Syndrome (IBS) and painful intestinal spasms. The core therapeutic domain is the symptomatic treatment of irritable bowel syndrome and related spastic conditions.

Targeted Symptom Support

The medication is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as recurrent abdominal pain, cramps, and associated bloating. In these situations, the therapy contributes to easing the overall symptom load.

“The therapy provides supportive relief when symptoms become more noticeable, and may assist with maintaining functional stability when symptoms are more noticeable.”

Quick Fact: Relief for Intestinal Spasms and IBS Discomfort

Patient Benefits

By addressing these core symptoms, this medication contributes to improved day-to-day comfort during symptomatic periods. This support assists with maintaining functional stability when symptoms create noticeable functional strain.

Who Can and Cannot Use Спазмомен? — Official Regulatory Information

Eligibility for Спазмомен (Otilonium Bromide) is strictly defined by regulatory documents, distinguishing between populations permitted, restricted, or contraindicated for use.

Contraindications and Restrictions

Use is absolutely contraindicated for patients with known hypersensitivity (allergy) to Otilonium Bromide or any of its excipients. Non-eligibility also extends to those with rare hereditary problems, specifically galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

Population Group	Regulatory Status
Children & Adolescents (<18)	Not Recommended (Safety/efficacy not established)
Pregnancy & Lactation	Use Conditional (Only if absolutely necessary/medical supervision)
Glaucoma, Prostatic Hypertrophy	Use With Caution is required

Eligible Populations

Adults aged 18 years and older are the primary eligible group. Use is permitted in Older Adults (Geriatric), and no dose adjustment is necessary for patients with documented renal impairment or hepatic impairment (kidney or liver issues). The eligibility status is determined by regulatory agencies to ensure the medicine is used only within its formally established population limits.

Interactions with other medicines and products

The official regulatory profile for Otilonium Bromide (the active ingredient in Спазмомен) reflects the current status of documented interaction data, which indicates a low expectation of clinical relevance. Specific drug-drug, drug-food, or drug-substance interactions are not formally listed in the prescribing information provided by health authorities.

Interaction Scope	Official Regulatory Assessment
Medicinal product categories with documented interactions	None documented in the regulatory label.
Specific interacting medicines	No specific drugs are listed as interacting substances.
Mechanistic basis of interactions	Not applicable; the effect on gastrointestinal transit is formally assessed as "not relevant" for the absorption of other co-administered oral medicines.
Timing-based interaction rules	None established for co-administration with other therapeutic agents.

The regulatory documentation provides a classification of No Relevant Interaction Risk at the recommended therapeutic dose. This assessment is based on the formal conclusion that the effect of the drug on the total gastrointestinal transit time is not expected to significantly alter the systemic exposure (absorption) of other oral medications.

Interaction Classifications	Official Regulatory Assessment
Interaction severity classification	Not classified as having clinically significant interactions.
Interaction-context constraints	Applies to the product when taken at the recommended dose.

Connection to the overall interaction profile: The interaction profile is formally defined by a lack of documented interaction patterns with other medicines. The official statements confirm that no restrictions or mandatory timing rules are established because the product's poor systemic absorption and local effect on the gastrointestinal tract are assessed as not clinically relevant to the absorption of concurrently administered oral drugs.

The mechanism of action for Спазмомен (Otilonium bromide) is characterized by a multi-target mechanism localized primarily to the smooth muscle and enteric nervous system of the distal gastrointestinal tract. This action is peripheral, minimizing systemic exposure.

Dual-Action Modulation of Smooth Muscle Contraction

Otilonium bromide acts as a Calcium ( Ca^2+) channel inhibitor, restricting the influx of extracellular Ca^2+ ions required to initiate and maintain muscle contraction. Concurrently, it functions as a competitive antagonist at muscarinic and tachykinin NK2 receptors found on enteric neurons and smooth muscle cells. This dual-action of channel inhibition and receptor antagonism suppresses the excitability of the gut wall, leading to smooth muscle relaxation and antispasmodic activity.

Localized Pathway Interference

Due to its chemical properties, the drug is concentrated at the site of action, allowing it to exert a targeted influence over specific enteric nervous system pathways. By modulating the NK2 receptor pathway, the mechanism also alters afferent nerve signaling, contributing to the reduction of overactive physiological responses and modulating gut motility patterns.

How to Use Спазмомен: Administration Guidelines

The use of Спазмомен (Otilonium Bromide) is governed by a defined set of instructions. These guidelines establish the standardized method, frequency, and timing for administering the medication.

The core administration principles specify that the medication is for oral use only, supplied as a 40 mg film-coated tablet. The adult dosing regimen involves a single dose of 40 mg, typically administered 2 to 3 times daily to achieve a total daily intake of 80–120 mg.

---

Administration Requirements

Instruction	Guideline
Route of Administration	Oral administration.
Tablet Intake	Must be swallowed whole with water; the tablet should not be crushed or chewed.
Timing	Administered before a meal (e.g., approximately 20 minutes prior).
Duration of Use	Typically prescribed for a period of 2 to 3 months, though the duration is based on clinical assessment of the patient's condition.

---

Population-Specific Rules

Group	Administration Rule
Pediatric Use	Use is not recommended for patients who are under the age of 18 years.
Missed Dose	If a dose is missed, the subsequent dose should not be doubled to compensate.

These procedures ensure the proper administration of the medicine.

Research Evidence / Overview of studies for Спазмомен

Research Evidence for Irritable Bowel Syndrome (IBS)

Research into Otilonium Bromide was studied for its use in adults diagnosed with Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating or episodic manifestations. The primary research consists of multiple Randomized Controlled Trials (RCTs), where the medicine was evaluated in studies that included a placebo for comparison. These trials typically observed responses over defined time intervals that often lasted between 10 to 15 weeks of active treatment. Systematic reviews and meta-analyses were also conducted, pooling findings from several trials that focused on similar study populations.

The outcomes related to physical discomfort were examined in these studies. Research explored the change in patient-reported symptoms, specifically monitoring the frequency and intensity of abdominal pain and the severity of abdominal bloating or distention. Findings describe patterns observed in the studies, reporting outcomes related to these key areas of patient-reported discomfort.

Studies on Painful Intestinal Spasms

Research examined the underlying symptom of painful spasms. This research explored the medicine in relation to measures of intestinal hypermotility and muscle activity. This evidence is often derived from the same Randomized Controlled Trials and pharmacological studies conducted for the main IBS indication. Studies monitored outcomes capturing phases of heightened symptom activity, and the findings contribute to understanding symptom patterns related to intestinal overactivity.

Examining Long-Term Studies and Durability of Response

The existing research base provides context but not individual predictions regarding the use of the medicine over extended periods. Core clinical trials monitored follow-up durations that were limited, typically spanning up to 15 weeks of active use. Research examined the symptom recurrence interval by tracking the time to symptom relapse after participants stopped taking the medicine. Studies report how symptoms evolved in the observed populations during these post-treatment phases, with some research describing patterns related to the return of symptoms. Therefore, long-term effects are not fully established, and there is limited information for long-term outcomes.

What Remains Uncertain in the Research Landscape

While a body of research exists, there are acknowledged limitations that contribute to understanding symptom patterns but also highlight areas where certainty remains low. For example, studies exploring short-term symptom changes provided mixed findings or noted no significant changes related to the normalization of bowel habits, such as stool frequency or consistency. Findings indicate patterns observed in the studies related to pain and cramping, while studies monitored bowel function outcomes, which were not consistently observed. Furthermore, some foundational large-scale trials relied on older diagnostic criteria for IBS, and the comparative evidence is lacking.

Key Studies & References

1. Submission for the classification of Otilonium bromide - 40 mg - Medsafe (Regulatory Document)

Common questions about Спазмомен (FAQ)

Q: Is Спазмомен only prescribed for problems in the stomach or intestines?

Official regulatory documents state that this medicine is indicated for treating painful, spastic (cramping) states of the distal parts of the intestinal tract, which includes the colon and rectum. It is also used for the symptomatic treatment of Irritable Bowel Syndrome (IBS).

Q: Are there any long-term health concerns associated with prolonged use of Спазмомен?

Studies suggest that because the medicine is poorly absorbed into the bloodstream (minimal systemic absorption), it is generally well tolerated and assessed as suitable for long-term use in managing IBS symptoms. Clinical data indicates the drug is well tolerated over extended periods.

Q: Does official information advise against using alcohol while taking Спазмомен?

Specific interactions between this medicine and alcohol are generally considered unknown in the official regulatory documents. As a standard safety precaution, official guidance recommends consulting a healthcare professional regarding alcohol consumption during use.

Q: Are there any food or beverage restrictions mentioned in the drug information?

Official product information advises that the medicine should be taken on an empty stomach or as prescribed. This administration requirement dictates the timing of the dose but does not typically include restrictions on the type of food or beverage you consume.

Q: Can Спазмомен cause dry mouth or constipation?

Regulatory documents list dry mouth as an uncommon side effect, meaning it may affect up to 1 in 100 people. Constipation is not listed among the frequently reported side effects in the official safety profile.

Q: Why is the timing of food sometimes mentioned in relation to taking this medicine?

The recommendation to administer the medicine on an empty stomach (such as approximately 20 minutes before a meal) is related to its properties. This timing is described as supporting optimal delivery and subsequent localized action in the gut wall.

Q: What is the meaning of the term 'contraindication' for this medicine?

A contraindication is a term used in regulatory documents to define a medical condition or situation where the medicine must not be used. These are strict rules established for safety reasons and define a population that is excluded from treatment.

Q: What should be done if an allergic reaction is suspected?

Official safety documents state that rare adverse events, such as allergic skin reactions or swelling (angioedema), can occur. If a severe reaction is suspected, official guidance states that immediate medical attention should be sought.

Q: How quickly does the effect of Спазмомен usually begin?

Official regulatory documentation states that the precise time frame for when the medicine begins to show its action is not clinically established. The onset of effect can vary based on the individual and the underlying condition being addressed.

Q: What is the typical duration of action for a single use of Спазмомен?

According to official documents, the amount of time for which this medicine remains active in the body from a single dose is not clinically established. The duration of symptom relief is addressed by the administration frequency prescribed by a doctor.

Q: Is a feeling of drowsiness or tiredness common after using Спазмомен?

Drowsiness and tiredness are not listed as common or uncommon adverse effects in the medicine's clinical trial data. Furthermore, regulatory assessments indicate the medicine has no or negligible influence on a person's ability to drive or use machines.

Q: Is Спазмомен officially restricted for people with certain heart problems?

While the medicine has specific warnings for conditions like glaucoma (increased eye pressure) and prostatic enlargement, severe heart problems are generally not listed as an absolute contraindication. Official information describes that the medicine is used with caution in patients who have certain pre-existing conditions.

Q: Why do some sources mention blurred vision as a possible effect?

The active ingredient, otilonium bromide, is a type of antispasmodic. Regulatory information highlights that the medicine is effective at therapeutic doses that typically do not produce certain side effects associated with similar drugs, such as blurred vision.

Q: Does Спазмомен contain any narcotics or controlled substances?

The active substance, Otilonium Bromide, is chemically classified as a quaternary ammonium derivative (an anticholinergic agent). It is not listed as a narcotic or controlled substance by government regulatory agencies.

Q: Is there a risk of becoming physically dependent on Спазмомен?

Official safety documents and clinical data indicate that no habit-forming tendencies have been reported for this medicine. It is not associated with the risk of physical dependence.

Q: Do official documents mention any potential for withdrawal effects when stopping Спазмомен?

Official safety information does not detail any specific withdrawal effects upon cessation of the drug. However, discontinuing treatment may be followed by a return or relapse of the original symptoms of the underlying condition.

Q: Is it safe to drive or operate machinery while the medicine is active?

According to the regulatory safety assessment, the medicine is stated to have no or negligible influence on the ability to drive and use machines. This means that the drug is not expected to cause impairment of attention or motor function.

Official Storage and Disposal Requirements

SpasmoMen (otilonium bromide) must be stored under specific environmental conditions to ensure product quality and integrity, as required by regulatory labeling.

Storage Requirement	Official Condition
Temperature	Store at or below 30 C (Do not store above 30 C).
Protection	Keep in the original package (outer carton) to protect from light.
Child Safety	Keep this medicine out of the sight and reach of children.
Stability Limit	Do not use after the expiry date printed on the carton.

For disposal, regulatory documents provide mandatory instructions to protect the environment. The medicine must not be thrown away via wastewater or household waste. Patients are instructed to consult their pharmacist on how to discard unused medicine or to dispose of all waste material in accordance with local regulatory requirements.